spacer
home > ebr > autumn 2017 > eu impact
PUBLICATIONS
European Biopharmaceutical Review

EU Impact

25 May 2018 is an important date for pharmaceutical companies, CROs, software vendors and others supporting drug development, as this is when the new EU General Data Protection Regulation (GDPR) – what the EU calls “the most important change in data privacy regulation in 20 years” – comes into effect (1).

The new rules replace the 1995 Data Protection Directive 95/46/EC and are meant to harmonise data privacy laws across Europe, as well as “to protect and empower all EU citizens’ data privacy”. The GDPR will have a significant impact on how patient data are handled as it changes the way organisations approach information security.

When GDPR comes into effect, national governments will not be required to pass enabling legislation. The regulation will be applicable immediately, and serious violations may result in fines of €20 million or 4% of the organisation's worldwide revenues.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Jon Weisberg, Industry Advisor for EBR, heads public relations and communications for SAFE-BioPharma Association. He provides comprehensive editorial and consulting services to life sciences organisations.
spacer
Jon Weisberg
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Automated testing of pharmaceutical packaging

Test-result reproducibility and traceability are essential when testing pharmaceutical packaging and medical products. Zwick has developed a robotic testing system for automated testing applications ranging from childproof bottles (withpress-and-turn caps) to auto-injectors and insulin pens; tests on these include determination of the release force. As well as increasing specimen throughput and reducing per-specimen costs, automation reduces operator influence, while releasing laboratory staff for more demanding activities in line with their skills and qualifications.
More info >>

White Papers

Pharmacovigilance and Risk Management Information in Centralised Applications in the EU

United BioSource Corporation (UBC)

Getting a new medication approved for the EU market through the centralised procedure can be complex and needs expertise. The new EU pharmacovigilance legislation (Good Vigilance Practice, GVP) is now in effect and applicants need to be fully compliant. It is critical to have a thorough understanding of the regulatory process and requirements, and the expectations with regards to the pharmacovigilance system and the risk management plan. Ensuring consistency and an appropriate level of detail in the documentation submitted as part of the approval process will help prevent unnecessary delays.
More info >>

 
Industry Events

SAPHEX 2018

1-2 November 2018, Gallagher Convention Centre, Midrand, South Africa

The SAPHEX exhibition and conference is now established as the “go-to” networking and business event for anyone working in the South African pharmaceutical manufacturing industry.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement